[The study on the tolerability of perindopril in patients with stable coronary heart disease].
OBJECTIVE
To evaluate the tolerability of perindopril dose-adjustment from 4 mg/d to 8 mg/d in Chinese patients with stable coronary heart disease (CHD).


METHODS
CHD patients with or without hypertension were eligible to this open lebel, multicenter study. Before admission, all patients received and tolerated perindopril 4 mg/d for at least 1 month. Adverse events, blood pressure, heart rate, Na(+), K(+), Cr, BUN at baseline, week 4 and week 8 were recorded.


RESULTS
A total of 109 patients with stable CHD were included in this study, 18 out of 109 (16.5%) patients experienced mild adverse events during observation period. No serious adverse event was recorded. Perindopril 8 mg/d was well tolerated in 102 patients (93.6%). One patient (0.9%) withdrew from the study because of severe cough. In patients with elevated baseline blood pressure, switching perindopril from 4 mg/d to 8 mg/d significantly lowered blood pressure from (149.4 +/- 7.6)/(84.1 +/- 11.0) mm Hg (1 mm Hg = 0.133 kPa) to (128.8 +/- 14.2)/(79.5 +/- 8.9) mm Hg (P < 0.01). Serum electrolytes, creatinine and BUN were stable during study period.


CONCLUSIONS
Perindopril 8 mg/d can be well tolerated by Chinese patients with stable coronary heart disease.
Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. xswy_pumc@yahoo.com.cn
Yan
Xiao-wei
XW
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure; D003327:Coronary Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril